Bayer CropScience Ltd to acquire up to 53.5 lakh shares from promoter Bayer CropScience AG, 11.91% of equity

What Bayer CropScience Ltd announced

On 1 July 2026, Bayer CropScience Ltd (the Target Company) filed a disclosure with BSE under Regulation 10(5) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing states that Bayer AG, a promoter of the Target, has agreed to acquire up to 5,354,030 equity shares from another promoter, Bayer CropScience AG, using the block‑deal mechanism. The proposed acquisition will be undertaken on or after 8 July 2026.

"The Acquirer will acquire up to 53,54,030 equity shares from the Seller, amounting to up to 11.91 % of the existing paid‑up equity share capital of the Target Company." – BSE filing, 1 July 2026

Details of the inter‑promoter share transfer

• Acquirer: Bayer AG (promoter of Bayer CropScience Ltd).
• Seller: Bayer CropScience AG (another promoter of the same company).
• Number of shares: Up to 5,354,030 shares.
• Percentage of capital: Up to 11.91 % of the Target’s paid‑up equity share capital.
• Proposed acquisition date: On or after 8 July 2026.
• Price ceiling: The shares will be bought at a price not exceeding the limits prescribed in Regulation 10(1)(a), specifically no more than 25 % above the volume‑weighted average price (VWAP) of Rs 4,434 per share calculated over the 60 trading days preceding the notice.
• Mechanism: The transaction will be executed as a block deal, a method that allows large share transfers without affecting market price significantly.
• Rationale: The filing describes the move as an inter‑se transfer of equity shares amongst two promoters of the promoter group, aimed at restructuring shareholding within the group rather than bringing in external investors.

Regulatory framework and exemptions

The acquisition falls under Regulation 10(1)(a) of the SEBI Takeover Regulations, which governs substantial share acquisitions. However, the filing notes that the acquirer is exempt from the mandatory open‑offer requirement because both the acquirer and the seller are promoters who have been associated with the Target for at least three years prior to the transaction, satisfying the exemption criteria in sub‑clause (ii) of Regulation 10(1)(a)(ii).

Key regulatory points from the filing:

• The acquirer confirms that the price will not exceed 25 % above the VWAP (Rs 4,434).
• Both parties have complied with all disclosure requirements under the Takeover Regulations for the preceding three years.
• The transaction is classified as a frequently traded stock, and the VWAP is used as the price reference.

Key facts at a glance

Why this matters for investors

The transaction is an intra‑group reshuffle rather than an external capital raise or a change of control. For existing shareholders, the key implications are:

• Shareholding dilution: The acquisition does not create new shares; it merely transfers ownership between promoters, so the total share count remains unchanged.
• Pricing discipline: By capping the purchase price at 25 % above the VWAP, the deal limits any premium that could affect the market valuation of the shares.
• Regulatory compliance: The exemption from an open offer removes the need for a public tender, meaning no immediate cash outflow to minority shareholders.
• Visibility of promoter intent: The move signals that the promoter group is consolidating its stake, which may be interpreted as confidence in the company’s long‑term prospects, though the filing does not provide any forward‑looking statements.

Conclusion

Bayer CropScience Ltd has disclosed an inter‑promoter acquisition of up to 5.35 million shares, representing roughly 12 % of its equity, to be executed via a block deal on or after 8 July 2026. The transaction is exempt from the mandatory open‑offer requirement because both parties qualify as long‑standing promoters. While the share count remains unchanged, the restructuring may affect the relative influence of each promoter within the company. The filing satisfies all SEBI disclosure obligations, and no further regulatory approvals are indicated as pending.